Bio Protocol launches OpenLabs, a platform that combines AI-powered R&D, community funding, and on-chain governance, as its ecosystem exceeds $33 million in funding.
summary
- Bio Protocol launches OpenLabs, which brings together AI-assisted R&D, collaboration, and funding into one platform.
- Researchers can seek funding through community voting, where BIO token holders participate in governance decisions.
- Bio Protocol announced that its BIO Genesis initiative has raised more than $33 million to support decentralized science projects.
According to Bio Protocol, the platform was introduced on June 19 during DeSci.Berlin 2026, an event held at the König Gallery as part of Berlin Blockchain Week.
The project says OpenLabs is designed to help researchers develop scientific ideas, coordinate with contributors, and raise funding through a single interface, rather than relying on separate grant applications, governance platforms, and collaboration tools.
At this event, Bio Protocol introduced OpenLabs as an alternative to the traditional research funding process, which often involves long review cycles and institutional oversight. The project says AI-powered workflows will help researchers develop and refine their projects, while community members can vote on research proposals.
Despite the launch, BioProtocol (BIO) continued to fall along with the broader crypto market. The token has fallen more than 8% in the past 24 hours as investors appreciated the hawkish tone adopted by US Federal Reserve Chairman Kevin Warsh and the uncertainty surrounding the implementation of the proposed US-Iran peace framework.
OpenLabs combines research collaborations and funding decisions
In the model described in Bio Protocol, researchers and community participants work within the same platform where project development and funding decisions are made. BIO tokens serve as governance and utility assets used for voting and ecosystem participation.
Bio Protocol focused on two projects during its launch. According to the team, RheumaAI is being developed as an AI agent focused on rheumatology research, while PeptAI is focused on peptide discovery.
With this project, OpenLabs says it will integrate AI-driven processes into scientific collaboration and enable token holders and community members to participate in funding decisions. Rather than relying solely on traditional grant committees, project proposals can be reviewed and supported through the platform’s built-in community governance mechanisms.
DeSci.Berlin has traditionally served as a venue for decentralized science initiatives. According to Bio Protocol, previous editions of this conference have helped foster projects such as Molecule Labs.
Bio Protocol expands decentralized scientific infrastructure
OpenLabs forms part of Bio Protocol’s existing decentralized science strategy. The project says it is developing an infrastructure that uses tokenized intellectual property and BioDAO to direct funds to biotechnology and scientific research programs.
Bio Protocol said its BIO Genesis initiative has raised more than $33 million to date. The project describes BIO Genesis as a funding mechanism that supports research-focused organizations operating within its ecosystem.
The collaboration between Bio Protocol and AI research tools predates OpenLabs. In August 2025, the project launched an ignition sale for Aubrai, a decentralized BioAgent developed with VitaDAO for longevity research. According to Bio Protocol, Aubrai will act as an on-chain AI co-scientist that can generate hypotheses and help design laboratory experiments.
According to Bio Protocol, the decentralized science sector is looking to apply blockchain-based systems to research funding, governance, and intellectual property management. Proponents of this model argue that transparent funding records and community participation can provide an alternative to traditional research funding structures.
As these models evolve, regulatory questions remain a potential challenge. Tokenized intellectual property associated with biotechnology projects intersects with securities regulations, patent frameworks, and pharmaceutical regulatory requirements.
As research programs progress from early-stage concepts to commercial development, legal and compliance obligations can become more complex for projects operating in the decentralized scientific field.
